An Australian stem cell and regenerative medicine company

October 23, 2018

GvHD trial results and implications

An interview with Cynata Vice President of Product Development Dr Kilian Kelly provides details on the important implications of Cynata’s recent successful clinical trial in graft-versus-host disease (GvHD).

September 09, 2018

Cynata Therapeutics' market-disruptive regenerative medicines complete world-first trial

Dr Killian Kelly, Cynata’s Vice President of Product Development spoke to Proactive Investors at the recent ASX Small and Mid-Cap Conference in Sydney.

Read entire story

July 05, 2018

Cynata CEO Dr Ross Macdonald interviewed on Sky News, Wednesday 4 July

Dr Ross Macdonald is interviewed by Nadine Blayney of Sky News Business - Tech.Biz

You can watch the full interview on the link below, starting at timecode: 10:10s

https://www.skynews.com.au

May 08, 2018

Stem cell researcher Cynata edges closer to treating ‘devastating’ disease

Read the special report published in “Stockhead”, a journalistic news service dedicated to covering the stories of emerging, ASX-listed companies

Read Report

December 12, 2017

Cynata To Drive Investor Support in Japan

Cynata is pleased to inform investors that, following the engagement of Japan- based investor relations firm Finantec Co., Ltd. (as announced on the 9th of August 2017), a series of investor briefings will be conducted in Japan this week to further raise awareness among the Japanese investor community.